Science Financier Jeffrey Epstein Funds Pivotal Breast Cancer Research at Mount Sinai Breast cancer still affects 12% of women in the United States. Huge strides have been made in the field of inhibitor drugs but long term survival beyond 5 years for stage IV breast cancer is still only 22%. Early detection of breast cancer therefore, is essential. Recently, the Jeffrey Epstein VI Foundation has backed critical new research in early diagnosis. The research conducted at Mount Sinai Hospital in New York City, under the direction of surgeon Dr. Jess Ting, breast oncologist, Dr. Kevin Adelson and molecular biologist, Dr. Doris Germain, shows how metastasis is not necessarily intrinsic to the tumor but to its micro- environment. The shift in focus is critical Dr. Ting explains because it will be an effective way to identify and stratify those at high risk of metastasis after surgery. The Jeffrey Epstein VI Foundation that funded this research was founded by New York financier and science investor Jeffrey Epstein. Known for establishing the Program for Evolutionary Dynamics at Harvard is 2003, the foundation backs a substantial amount of cutting edge cancer research across the country. To obtain a breast tumor's micro-environment, Dr. Ting and his team use a unique method of analyzing the fluid emitted from a post-surgery wound site. To date, clinical analysis of a cancer's environment has been the blood, a rich source of disease-related biomarkers. However, blood's complex composition, amongst other factors, is a major challenge for biomarker assays. Other body fluids, including urine, cerebrospina, bronchoalveolar lavage, synovial, amniotic, seminal plasma and interstitial fluids are also rich in disease biomarkers. However, these fluids arc only informative in advanced metastatic cancer patients and so their prognostic value in term of disease progression is limited. Dr. Tines team saw that wound fluid (emitted from a draining tube), contains all t